Whitehawk Therapeutics (WHWK) FCF Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has 7 years of FCF Margin data on file, last reported at 173.76% in Q1 2025.

• FCF Margin for Q1 2025 came in at 173.76%, up 20719.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 1371.38% (down 113775.0% YoY), and the FY2025 annual result was 1371.38%, down 113775.0% from the prior year.
• FCF Margin grew to 173.76% in Q1 2025 per WHWK's latest filing, from 203.59% in the prior quarter.
• Over five years, FCF Margin peaked at 8802.5% in Q1 2021 and troughed at 842.57% in Q1 2022.
• A 5-year average of 330.53% and a median of 213.31% in 2023 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 964507 bps in 2022, then jumped 47275 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 88.77% in 2021, then slumped by 145 bps to 217.87% in 2022, then climbed by 2 bps to 213.31% in 2023, then increased by 5 bps to 203.59% in 2024, then gained by 15 bps to 173.76% in 2025.
• Business Quant data shows WHWK's FCF Margin at 173.76% in Q1 2025, 203.59% in Q4 2024, and 229.67% in Q3 2024.